Conference Documentation: Pharmaceutical Portfolio & Product Life Cycle Management
SMI Publishing, Ltd
June 28, 2010 SKU: SMI2774889
|
|
Developing promising portfolios into a profitable revenue stream in such a highly regulated and resource limited environment is a challenging undertaking. It is therefore essential to understand how to build an optimal mix of innovative projects within a portfolio, introduce them quickly and manage them effectively and efficiently.
SMi’s 5th Annual Pharmaceutical Portfolio & Product Life Cycle Management Conference will provide an unmissable learning and networking opportunity with the leading experts from the world of Portfolio and Life Cycle Management. Offering you exceptional insight into:
- Improving accuracy in tracking and managing pharmaceutical projects
- Cutting the costs of developing new products
- The latest developments and issues in the regulatory landscape
- Optimisation of portfolio planning and project scheduling
- Route to efficient resource allocation
- Defining and planning major operational projects
Learn from the industry experts, through firsthand accounts, how to evaluate and improve project and portfolio performance. Book your delegate place now to avoid missing out.
|
- DAY 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Tony Ellery, Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Novartis Ophthalmics.
- 9.10 Portfolio Management Helping in the Valuation of Projects in Late Discovery Research and Early Development
- Alignment of evaluation methodologies from discovery through early development to late stage development and life cycle management
- Key parameters to be considered in the evaluation of projects
- Alignment with therapeutic area and organisational strategies and objectives
- Use of multi attribute analysis methods within UCB portfolio management
- John Bird, Director Portfolio Management, UCB Pharma.
- 9.50 Portfolio Modelling in Support of Strategy
- Why model, for whom, what decisions over what timeframe?
- Understanding historical data
- Modelling and decision making of the early stage portfolio
- Future trends: Externalisation, Resources and Portfolio diversity
- Leanings and challenges
- Michael O'Grady, Portfolio-Analysis Manager, GlaxoSmithKline.
- 10.30 Morning Coffee
- 11.00 Reflection on Pivotal Points in (R&D) Portfolio Management
- Holistic and flexible portfolio management at Bayer Schering Pharma
- The role and the perception of target product profiles
- Who decides before a project reaches clinical proof of concept
- How could regional perspectives be reflected in prioritizing R&D assets?
- Harald Nusser, Head of Portfolio Management, Bayer Schering Pharma.
- 11.40 What Happens to the Market When Major Brands Lose Exclusivity? Measuring the 'Class Effect' and Planning the Response
- Choosing comparator products and markets
- Forecasting considerations
- Options for life cycle management
- Do's and don’t's
- Simon Shohet , Practice Leader, UK Product & Portfolio Strategy Consulting , IMS Health.
- 12.20 Networking Lunch
- 1.20 Applications of ImSus® Technology for Product Lifecycle Management
- Rationale for controlled-release depot formulations
- Advantages of ImSus® technology
- Field of application
- Formulation of protein, peptide, small molecule drugs
- Examples for successful product lifecycle management
- Celal Albayrak, CEO , Alrise Biosystems GMBH.
- 2.00 Portfolio Optimisation and Project Prioritisation
- Similarities and Differences of Portfolio Optimisation and Project Prioritisation
- Common parameters and tools
- The different perspectives required for optimization and prioritisation
- Roger Holdsworth, Head - R&D Portfolio Management, UCB Group.
- 2.40 Portfolio Value and Risk Assessment
- Assessing project and portfolio risks
- Value scenarios and ranges
- Monte Carlo simulations for portfolio analyses
- Kimber Hardy, Head of Valuation and Analysis, Portfolio Management , Merck Serono.
- 3.20 Afternoon Tea
- 3.40 R&D Portfolio Management in Companies of Different Sizes
- Tasks and challenges of portfolio management in large, mid-size, and small companies: commonalities and differences
- Appropriate analytical tools
- Portfolio management process
- Creating a sustainable portfolio by proactively managing portfolio risk
- Kerstin Bode-Greuel, Co-Founder & Managing Director, Bioscience Valuation.
- 4.20 The Human Factor in Portfolio Management
- People obstacles in portfolio management
- Case studies
- The political, emotional and rational dimensions
- Management processes in R&D, committees, etc.
- Implementing effective portfolio management in a complex organisation
- Techniques to manage the people
- Brian Roche, Director, Conseptua Consulting Ltd.
- 5.00 An EU Perspective on Patents, SPCs and Paediatric Extensions in Life Cycle Management
- Patents: polymorphs, stereochemistry and new formulations
- SPCs (EU patent extensions): limitations
- Paediatric extensions in the EU: latest case law
- Antitrust concerns: the EU Pharma Sector Inquiry
- Andrew Sharples, European Patent Attorney, McDermott Will & Emery.
- 5.40 Chairman’s Closing Remarks and Close of Day One
-
-
-
- DAY 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Tony Ellery, Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Novartis Ophthalmics.
- 9.10 Integrated Approach to Portfolio Management and LCM
- How to build effective portfolio management based on LCM
- What are the main obstacles
- Best practices how to overcome the obstacles
- Pasi Piitulainen, Senior Director, Business and Science Affairs, Actelion Pharmaceuticals.
- 9.50 Healthcare Modeling: Simulation Modeling in Portfolio Prioritization
- The Archimedes Model: Structure and Function
- The Archimedes Model: Validation through Clinical Trial Simulation
- Case Study: Prioritization of Interventions in Metabolic Disease
- David Eddy, Chief Medical Officer and Founder, Archimedes.
- Mika Newton, Director of Sales, Archimedes.
- 10.30 Morning Coffee
- 11.00 Forecasting Analysis and Incorporating Risk and Uncertainty
- Different approaches to forecasting
- Forecasting in the changing dynamics of the pharmaceutical industry
- Forecasting the unpredictable - mitigating the risk
- Peter Raun, Head of Department, Branded products, H.Lundbeck.
- 11.40 Case study: How to Integrate Early Life Cycle Management in Drug Development?
- Unusual development approaches to reach market early
- Acceleration of phase transition as a tool for effective drug
- Early mapping of product opportunity for effective implementation of life cycle management
- Marie Bernasconi, Global Program Team Director, Novartis.
- 12.20 Networking Lunch
- 1.20 Generic Biotech: Science of Politics
- A rational pathway for generic biotech medicines through FDA
- The political barrier to generic biologics
- Where the developments lies
- Costs of generic biotech and profits of brand biotech
- William Haddad, Chairman / Chief Executive Officer, Biogenerics Inc Representing Cipla Ltd (India).
- 2.00 Strategic Implications for Pharmaceuticals in Recent US Patent Law Developments
- New rules for patent term extension based on delays in the US Patent and Trademark Office—appeals v. requests for continued examination
- Protecting existing drugs with novel delivery systems
- Claims to methods of action—when can they work?
- Other strategic considerations in the current environment
- Bruce Sunstein, Attorneys at Law, Sunstein Kann Murphy & Timbers LLP .
- 2.40 Afternoon Tea
- 3.00 Maximizing and Sustaining Pharmaceutical Brand Value with LCM
- Identifying strategies that will/won’t work in the face of tougher cost containment
- Organizing the company for successful LCM
- Creating integrated LCM plans
- Tony Ellery, Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Novartis Ophthalmics.
- 3.40 Adding Value Through New Product Development
- Challenges faced by pharmaceutical industry
- Constraints, myths and realities
- Innovations and their value
- Perceptions about life cycle and clinical benefits
- Karrar Khan, Former Director, Pharmaceutical Development, OSI Pharmaceuticals .
- 4.20 Chairman’s Closing Remarks and Close of Day Two
Share this report
Other tasks Related Markets Manufacturing, Packaging & Detailing Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
